Mechanism-linked potency assays drive gene therapy success
VectorBuilder’s Alan Griffith explains the value of MoA-reflective potency assays for gene therapy development and the benefits of working with assay specialists like Svar Life Science
Editor's picks
SelectScience show coverage
We're excited to be attending SLAS2026 to bring you the latest news, interviews, and expert insights from this year's conference
Stay up to date
Clinical Diagnostics
The global #CLINICAL24 2025 conversation has begun! Tell us your daily challenges and let's explore the solutions together
Explore topics
Environmental
Explore the science, regulations, and analytical strategies shaping the global response to PFAS contamination
Explore topics
